RxDoctor Payments Data

Wendy Bodwell

Psychiatric/Mental Health · Auburn, INNPI 1356957641

Payments from drug & device makers

$2,931in general payments, 2019–2025

Across 185 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$423
  • AbbVie$324
  • E.r. Squibb & Sons, L.L.C.$278
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$274
  • Supernus Pharmaceuticals, Inc.$255
  • Teva Pharmaceuticals USA, Inc.$249
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,931 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$11,478
Medicare patients
46
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$218,579
Abilify MaintenaAripiprazole61$184,139
Invega SustennaPaliperidone Palmitate25$89,826
VraylarCariprazine Hcl63$81,222
RexultiBrexpiprazole47$50,653
CaplytaLumateperone Tosylate26$42,308
TrintellixVortioxetine Hydrobromide82$39,964
NuedextaDextromethorphan Hbr/Quinidine27$32,513
VivitrolNaltrexone Microspheres13$23,005
Aripiprazole283$22,638
QuviviqDaridorexant Hcl14$6,974
Desvenlafaxine Succinate ErDesvenlafaxine Succinate73$4,948
Trazodone Hcl257$3,427
Quetiapine Fumarate ErQuetiapine Fumarate48$3,312
Divalproex Sodium ErDivalproex Sodium43$3,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$172$234,792108 claims
Neurocrine Biosciences, Inc.Ingrezza$224$218,57926 claims
Johnson & JohnsonInvega Sustenna$29$89,82625 claims
AbbVieVraylar$324$81,22263 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$274$42,30826 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$49$39,96482 claims
Avanir Pharmaceuticals, Inc.Nuedexta$81$32,51327 claims
Alkermes, Inc.Vivitrol$423$23,00513 claims
Idorsia Pharmaceuticals US IncQuviviq$14$6,97414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Auburn

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →